Belinda Chapman1, Monica Slavin2, Debbie Marriott3, Catriona Halliday4, Sarah Kidd5, Ian Arthur6, Narin Bak7, Christopher H Heath8, Karina Kennedy9, C Orla Morrissey10, Tania C Sorrell1,11, Sebastian van Hal12, Caitlin Keighley11, Emma Goeman3, Neil Underwood13, Krispin Hajkowicz14, Ann Hofmeyr15, Michael Leung6, Nenad Macesic16, Jeannie Botes17, Christopher Blyth18, Louise Cooley19, C Robert George20, Pankaja Kalukottege21, Alison Kesson22, Brendan McMullan23, Robert Baird24, Jennifer Robson25, Tony M Korman26, Stella Pendle27, Kerry Weeks28, Eunice Liu29, Elaine Cheong29, Sharon Chen4,11. 1. Westmead Institute for Medical Research, The University of Sydney, Sydney, NSW, Australia. 2. Department of Infectious Diseases, Peter MacCallum Cancer Centre, Victorian Infectious Diseases Service at the Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia. 3. Department of Microbiology and Infectious Diseases, St Vincent's Hospital, Sydney, NSW, Australia. 4. Centre for Infectious Diseases and Microbiology Laboratory Services, ICPMR, Westmead Hospital, Westmead, Sydney, NSW, Australia. 5. National Mycology Reference Centre, SA Pathology, Adelaide, SA, Australia. 6. Department of Microbiology, PathWest Laboratory Medicine, QEII Medical Centre, Nedlands, WA, Australia. 7. Department of Infectious Diseases, Royal Adelaide Hospital, Adelaide, SA, Australia. 8. Department of Microbiology and Infectious Diseases, Royal Perth Hospital, Department of Microbiology, PathWest Laboratory Medicine Fiona Stanley Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, WA, Australia. 9. Department of Infectious Diseases and Microbiology, Canberra Hospital, Australian National University Medical School, Canberra, ACT, Australia. 10. Department of Infectious Diseases, Alfred Health and Monash University, Melbourne, VIC, Australia. 11. Centre for Infectious Diseases and Microbiology Westmead Institute for Medical Research, Westmead Hospital and the Marie Bashir Institute for Infectious Diseases and Biosecurity, University of Sydney, Sydney, NSW, Australia. 12. Department of Infectious Diseases and Microbiology, Royal Prince Alfred Hospital, Sydney, NSW, Australia. 13. Infection Management Services, Princess Alexandra Hospital, Brisbane, Queensland, Australia. 14. Department of Infectious Diseases, Royal Brisbane and Women's Hospital, School of Medicine, University of Queensland, Brisbane, Queensland, Australia. 15. Department of Microbiology and Infectious Diseases, Liverpool Hospital, Sydney, NSW, Australia. 16. Department of Infectious Diseases, Austin Hospital, Heidelberg, VIC, Australia and Division of Infectious Diseases, Columbia University Medical Center, New York City, NY, USA. 17. Department of Microbiology, SEALS South Pathology, Wollongong Hospital, Wollongong, NSW, Australia. 18. School of Paediatrics and Child Health, University of Western Australia, Subiaco, WA, Australia and Department of Infectious Diseases, Princess Margaret Hospital, Subiaco, WA, Australia. 19. Department of Microbiology and Infectious Diseases, Royal Hobart Hospital, Hobart, Tasmania, Australia. 20. Department of Microbiology, South Eastern Area Laboratory Services, Prince of Wales Hospital, Sydney, NSW, Australia. 21. Department of Microbiology, Pathology -North, Hunter, Newcastle, NSW, Australia. 22. Department of Infectious Diseases and Microbiology, The Children's Hospital, Westmead and Discipline of Paediatrics and Child Health, University of Sydney, Sydney, NSW, Australia. 23. Department of Immunology and Infectious Diseases, Sydney Children's Hospital, Randwick, NSW, Australia. 24. Department of Microbiology, Royal Darwin Hospital, Darwin, NT, Australia. 25. Sullivan and Nicolaides Pathology, Brisbane, Queensland, Australia. 26. Monash Infectious Diseases, Monash University and Monash Health, Melbourne, VIC, Australia. 27. Department of Microbiology, Australian Clinical Laboratories, Sydney, NSW, Australia. 28. Department of Microbiology, Pathology North, Royal North Shore Hospital, Sydney, NSW, Australia. 29. Department of Microbiology and Infectious Diseases, Concord Hospital, Sydney, NSW, Australia.
Abstract
Objectives: Knowledge of contemporary epidemiology of candidaemia is essential. We aimed to identify changes since 2004 in incidence, species epidemiology and antifungal susceptibilities of Candida spp. causing candidaemia in Australia. Methods: These data were collected from nationwide active laboratory-based surveillance for candidaemia over 1 year (within 2014-2015). Isolate identification was by MALDI-TOF MS supplemented by DNA sequencing. Antifungal susceptibility testing was performed using Sensititre YeastOne™. Results: A total of 527 candidaemia episodes (yielding 548 isolates) were evaluable. The mean annual incidence was 2.41/105 population. The median patient age was 63 years (56% of cases occurred in males). Of 498 isolates with confirmed species identity, Candida albicans was the most common (44.4%) followed by Candida glabrata complex (26.7%) and Candida parapsilosis complex (16.5%). Uncommon Candida species comprised 25 (5%) isolates. Overall, C. albicans (>99%) and C. parapsilosis (98.8%) were fluconazole susceptible. However, 16.7% (4 of 24) of Candida tropicalis were fluconazole- and voriconazole-resistant and were non-WT to posaconazole. Of C. glabrata isolates, 6.8% were resistant/non-WT to azoles; only one isolate was classed as resistant to caspofungin (MIC of 0.5 mg/L) by CLSI criteria, but was micafungin and anidulafungin susceptible. There was no azole/echinocandin co-resistance. Conclusions: We report an almost 1.7-fold proportional increase in C. glabrata candidaemia (26.7% versus 16% in 2004) in Australia. Antifungal resistance was generally uncommon, but azole resistance (16.7% of isolates) amongst C. tropicalis may be emerging.
Objectives: Knowledge of contemporary epidemiology of candidaemia is essential. We aimed to identify changes since 2004 in incidence, species epidemiology and antifungal susceptibilities of Candida spp. causing candidaemia in Australia. Methods: These data were collected from nationwide active laboratory-based surveillance for candidaemia over 1 year (within 2014-2015). Isolate identification was by MALDI-TOF MS supplemented by DNA sequencing. Antifungal susceptibility testing was performed using Sensititre YeastOne™. Results: A total of 527 candidaemia episodes (yielding 548 isolates) were evaluable. The mean annual incidence was 2.41/105 population. The median patient age was 63 years (56% of cases occurred in males). Of 498 isolates with confirmed species identity, Candida albicans was the most common (44.4%) followed by Candida glabrata complex (26.7%) and Candida parapsilosis complex (16.5%). Uncommon Candida species comprised 25 (5%) isolates. Overall, C. albicans (>99%) and C. parapsilosis (98.8%) were fluconazole susceptible. However, 16.7% (4 of 24) of Candida tropicalis were fluconazole- and voriconazole-resistant and were non-WT to posaconazole. Of C. glabrata isolates, 6.8% were resistant/non-WT to azoles; only one isolate was classed as resistant to caspofungin (MIC of 0.5 mg/L) by CLSI criteria, but was micafungin and anidulafungin susceptible. There was no azole/echinocandin co-resistance. Conclusions: We report an almost 1.7-fold proportional increase in C. glabrata candidaemia (26.7% versus 16% in 2004) in Australia. Antifungal resistance was generally uncommon, but azole resistance (16.7% of isolates) amongst C. tropicalis may be emerging.
Authors: Renáta Tóth; Jozef Nosek; Héctor M Mora-Montes; Toni Gabaldon; Joseph M Bliss; Joshua D Nosanchuk; Siobhán A Turner; Geraldine Butler; Csaba Vágvölgyi; Attila Gácser Journal: Clin Microbiol Rev Date: 2019-02-27 Impact factor: 26.132
Authors: Emily E Ricotta; Yi Ling Lai; Ahmed Babiker; Jeffrey R Strich; Sameer S Kadri; Michail S Lionakis; D Rebecca Prevots; Jennifer Adjemian Journal: J Infect Dis Date: 2021-04-08 Impact factor: 5.226